about
Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GNCritical appraisal of eculizumab for atypical hemolytic uremic syndromeRecent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuriaStructural basis for therapeutic inhibition of complement C5Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal PathwayAn international consensus approach to the management of atypical hemolytic uremic syndrome in children.A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience.Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.Liver transplantation for aHUS: still needed in the eculizumab era?A Hispanic female patient with heartburn: A rare presentation of Paroxysmal Nocturnal Hemoglobinuria.Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease.A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic SyndromeNew milestones ahead in complement-targeted therapy.Paroxysmal nocturnal hemoglobinuriaComplement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Complement involvement in kidney diseases: From physiopathology to therapeutical targetingComplement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.Applying complement therapeutics to rare diseases.Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization.Complement activation, regulation, and molecular basis for complement-related diseasesParoxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemiaComplement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.Complement inhibition as potential new therapy for antibody-mediated rejection.Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.The genetics of drug efficacy: opportunities and challenges.Emerging Therapies in Antiphospholipid Syndrome.Targeting the complement cascade: novel treatments coming down the pike.From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.Structural insight into proteolytic activation and regulation of the complement system.Complementopathies.Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.Many drugs for many targets: novel treatments for complement-mediated glomerular disease.
P2860
Q26741542-775EB857-3B33-431F-B648-72C4C159A99BQ26750692-90211D3C-28D8-4368-8045-EAB15F3FE3FCQ26766624-04BD726B-994C-4BC7-A8A0-5F2640559F59Q27704314-E0FCF796-DBD0-4815-9B2D-659D8EF3FFD1Q27704898-90ABFC4F-18A6-4A2E-9261-F976E9760C3AQ33421861-3D110E69-1037-421C-B4B8-2AA2742C6C89Q33422224-524F1875-D9CB-400A-A197-A7DBADB0A6DBQ33424274-F46C7E35-19FA-4DF0-8029-42DAB46838EAQ33424946-88B064F9-24A0-4E17-B52F-730427E23935Q33425610-EAADACE0-3C2E-4CDD-BA2A-380B9AF8B2E1Q33427846-06CD6127-C455-4C16-8883-21B0250724CBQ33428978-863A8A16-02F8-46E1-AF36-2B11B5560BCBQ33436307-1DC7A1C3-EE37-4DA6-94AF-4374DDE42EF0Q33436512-162E3DE8-F3CE-489C-8647-4C0A46975C61Q33436972-7039F58A-10CF-4142-A8BE-02B81AC97B5DQ33437631-E4EDCA0A-9ABC-4BAC-B8D8-A0C66E5665FBQ33437634-3BBBAE93-8EAE-4CBB-AA63-E43D454B36C4Q33602320-E7DB114D-D005-4769-AE1C-5FF0BD5CC3ADQ34431429-F9C21FB2-4945-45E4-8171-FB7A7612DD46Q35252156-FC1EA889-7656-498D-B467-78593E01EBD6Q35567841-64D80F97-3B25-4B4E-BA73-9174BC41FC30Q36187306-FCCA720B-636E-4947-9225-7DC8FD39D551Q36315497-3E1B29D2-31D1-4C4D-B2FA-3586E2DDB5D5Q36364687-1B60B0C5-038C-46C3-BB1D-7FF60BBC4C90Q36380682-D2B5D39B-EC7C-4556-84D0-FAFB595D8DE5Q36416292-500460BE-87F5-4D69-A706-0160D582005CQ36460034-6E158FD4-5F1B-41D1-AA2E-AC507A753A32Q36563619-CD1A5B32-B7D1-4337-9A2F-86861F0C5511Q37497101-662635F5-F30E-4B5C-BF9E-848EC6766406Q38549182-544D2220-9694-4780-A5B1-C847C1194C91Q38609238-9E0858E6-F9A3-496A-8F4A-164F57F69982Q38718092-CCDA3845-BC98-42BC-AD30-03BF87B969EEQ38773033-45216677-EEBD-4A29-A645-509B96D0B048Q38782057-1E881124-3D5A-489A-B80F-CF335A220497Q38850489-F9148573-BC65-46A1-8BF4-127126393391Q38879877-9DD00E44-2235-41A6-8D9B-E27DD50EF969Q38991069-BF86E80C-89AE-487B-A51C-3CDD363B3887Q39142842-9639EF31-E1B0-4AC5-A64C-D6D446EBACC8Q39200048-B5373030-D6E7-4A6D-87B2-DDA96BCC2BA8Q39229285-FB2832B0-699F-4C7D-A6BF-ED6DBA881EC0
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Genetic variants in C5 and poor response to eculizumab.
@en
Genetic variants in C5 and poor response to eculizumab.
@nl
type
label
Genetic variants in C5 and poor response to eculizumab.
@en
Genetic variants in C5 and poor response to eculizumab.
@nl
prefLabel
Genetic variants in C5 and poor response to eculizumab.
@en
Genetic variants in C5 and poor response to eculizumab.
@nl
P2093
P356
P1476
Genetic variants in C5 and poor response to eculizumab.
@en
P2093
Andres L Brodsky
Hideyoshi Noji
Hirohiko Shibayama
Johji Inazawa
Jun-ichi Nishimura
Kazuma Ohyashiki
Kiyoshi Ando
Krista Johnson
Kunio Kitamura
P304
P356
10.1056/NEJMOA1311084
P407
P577
2014-02-01T00:00:00Z